FDA issues Complete Response Letter for CERTRIAD NDA

Download PDF Copy

Editorial Checklist

Reviewed

AbbottMar 31 2010

AstraZeneca and Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) for the New Drug Application (NDA) for CERTRIAD™ (rosuvastatin / fenofibric acid delayed release) Capsules. The companies are currently evaluating the CRL, will continue discussions with the FDA to determine next steps with respect to the CERTRIAD NDA and will respond to the agency's request for additional information.

Source:

Posted in: Pharmaceutical News

Tags: Education, Food, Neuroscience, New Drug Application, Oncology, Parkinson's Disease, Rosuvastatin

Comments (0)

Download PDF Copy

Suggested Reading

Better food, better mood: The role of diet quality in mental health

Better food, better mood: The role of diet quality in mental health

Ultra-processed foods dominate children's diets from toddlerhood to middle childhood

Ultra-processed foods dominate children's diets from toddlerhood to middle childhood

Frequent ultra-processed food consumption raises mortality risks, especially in women

Frequent ultra-processed food consumption raises mortality risks, especially in women

High levels of microplastics found in prostate tumors, possibly linked to take-out food

High levels of microplastics found in prostate tumors, possibly linked to take-out food

Key triggers for food allergies in children after organ transplants

Key triggers for food allergies in children after organ transplants

Social media normalizes unhealthy food choices, shaping youth habits and brand loyalty

Six common flying with food allergies myths

Six common flying with food allergies myths

Ultra-processed food linked to weight gain and lower well-being in adolescents

Ultra-processed food linked to weight gain and lower well-being in adolescents

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Ultra-processed foods increase active psoriasis risk, study shows